Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies
Latest Information Update: 02 Nov 2021
At a glance
- Drugs AV-COVID-19 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors AiVita Biomedical
- 01 Apr 2021 Status changed from active, no longer recruiting to completed.
- 25 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2021 New trial record